Kenneth C. Anderson – författare

This issue of Hematology/Oncology Clinics of North America, devoted to Multiple Myeloma, is edited by Dr. Kenneth C. Anderson. Articles in this issue include: Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma; Diagnosis and Risk Stratification in Myeloma; Treatment of Newly Diagnosed Transplant Eligible Patients; Treatment of Newly Diagnosed Transplant Ineligible Patients; Treatment of Relapsed/Refractory Myeloma; Maintenance Therapy; Novel Targeted Therapies; Novel Immune-based Therapies; Allotransplantation in Myeloma; and Waldenstrom's Macroglobulinemia.

Ever since the discovery of blood types early in the last century, transfusion medicine has evolved at a breakneck pace. This second edition of Blood Banking and Transfusion Medicine is exactly what you need to keep up. It combines scientific foundations with today's most practical approaches to the specialty. From blood collection and storage to testing and transfusing blood components, and finally cellular engineering, you'll find coverage here that's second to none. New advances in molecular genetics and the scientific mechanisms underlying the field are also covered, with an emphasis on the clinical implications for treatment. Whether you're new to the field or an old pro, this book belongs in your reference library.

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.

Myeloma is the second-most common hematologic cancer, accounting for approximately 1 percent of all cancers and 2 percent of all deaths from cancer. In recent years there have been major and significant advances in the diagnosis, imaging, molecular pathogenesis, and therapy of myeloma. This book describes these advances in a single, practical volume, placing them in the context of daily clinical practice. Different myeloma subtypes are discussed in individual chapters, integrating etiology, pathogenesis, molecular pathology, histology, and therapy in a single place for each condition. The book begins by discussing epidemiology, imaging techniques, pathogenesis, and other general considerations. Conditions covered in detail include multiple myeloma, POEMS syndrome, Castleman''s syndrome, Waldenstrom''s macroglobulinemia, amyloidosis and MGUS. Featuring color illustrations, and written and edited by leading authorities in the field, Myeloma provides readers with the information they need to diagnose and manage these complex disorders.

Myeloma is the second-most common hematologic cancer, accounting for approximately 1 percent of all cancers and 2 percent of all deaths from cancer. In recent years there have been major and significant advances in the diagnosis, imaging, molecular pathogenesis, and therapy of myeloma. This book describes these advances in a single, practical volume, placing them in the context of daily clinical practice. Different myeloma subtypes are discussed in individual chapters, integrating etiology, pathogenesis, molecular pathology, histology, and therapy in a single place for each condition. The book begins by discussing epidemiology, imaging techniques, pathogenesis, and other general considerations. Conditions covered in detail include multiple myeloma, POEMS syndrome, Castleman''s syndrome, Waldenstrom''s macroglobulinemia, amyloidosis and MGUS. Featuring color illustrations, and written and edited by leading authorities in the field, Myeloma provides readers with the information they need to diagnose and manage these complex disorders.

Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy. Introduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancerCovers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicineSummarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities

Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy. Introduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities

Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy. Introduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities

CANCER CONSULT New edition covering the specialties of hematology, oncology and cellular therapy, now in two volumes Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition includes hundreds of answers to practice-based questions covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of cancer. This textbook series also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. The book’s smaller size allows for easy access during medical rounds. This volume also includes: Up-to-date clinically relevant information on the very latest topics such as molecular techniques, targeted therapies, immunotherapy, BMT, CAR T-cell therapy and translational cancer researchSections on ALL, AML, myeloid neoplasms, CLL, Hodgkin’s and Non-Hodgkin’s lymphomas, amongst other topicsStreamlined, engaging content to make finding information easier and less time consuming for the readerConcise and practical expert perspectives that reference key studiesReferences to the latest NCCN, ESMO, ASH, ASTCT, EBMT and other national guidelinesWith its powerful focus on pragmatic clinical diagnostic, therapeutic and prognostic approaches, Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition will help keep hematology, oncology and cellular therapy practitioners up-to-date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base. It also offers clinicians, trainees, and fellows an excellent opportunity to enhance their preparation for the ABIM, hematology and oncology fellowship and recertification exams.

CANCER CONSULT

New edition covering the specialties of hematology, oncology and cellular therapy, now in two volumes

Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition includes hundreds of answers to practice-based questions covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of cancer. This textbook series also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. The book’s smaller size allows for easy access during medical rounds. This volume also includes:

Up-to-date clinically relevant information on the very latest topics such as molecular techniques, targeted therapies, immunotherapy, BMT, CAR T-cell therapy and translational cancer research Sections on ALL, AML, myeloid neoplasms, CLL, Hodgkin’s and Non-Hodgkin’s lymphomas, amongst other topics Streamlined, engaging content to make finding information easier and less time consuming for the reader Concise and practical expert perspectives that reference key studies References to the latest NCCN, ESMO, ASH, ASTCT, EBMT and other national guidelines

With its powerful focus on pragmatic clinical diagnostic, therapeutic and prognostic approaches, Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition will help keep hematology, oncology and cellular therapy practitioners up-to-date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base. It also offers clinicians, trainees, and fellows an excellent opportunity to enhance their preparation for the ABIM, hematology and oncology fellowship and recertification exams.

CANCER CONSULT

New edition covering the specialties of hematology, oncology and cellular therapy, now in two volumes

Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition includes hundreds of answers to practice-based questions covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of cancer. This textbook series also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. The book’s smaller size allows for easy access during medical rounds. This volume also includes:

Up-to-date clinically relevant information on the very latest topics such as molecular techniques, targeted therapies, immunotherapy, BMT, CAR T-cell therapy and translational cancer research Sections on ALL, AML, myeloid neoplasms, CLL, Hodgkin’s and Non-Hodgkin’s lymphomas, amongst other topics Streamlined, engaging content to make finding information easier and less time consuming for the reader Concise and practical expert perspectives that reference key studies References to the latest NCCN, ESMO, ASH, ASTCT, EBMT and other national guidelines

With its powerful focus on pragmatic clinical diagnostic, therapeutic and prognostic approaches, Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition will help keep hematology, oncology and cellular therapy practitioners up-to-date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base. It also offers clinicians, trainees, and fellows an excellent opportunity to enhance their preparation for the ABIM, hematology and oncology fellowship and recertification exams.

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.Moving from the bench to the bedside to the forefront of therapeutic development, this source:helps clinicians and researchers effectively deploy therapeutic strategies into clinical practicereflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapiesconsiders the critical role of the bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myelomadiscusses novel therapies in phase I and phase II trials, focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myelomaaddresses novel therapies for other plasma cell disorders, and provides the framework for the design of next generation agents and combination therapiescovers the entire scope of translational work in multiple myeloma, from advances in molecular pathogenesis, to prognostic factors, immunotherapy, and new options for newly diagnosed and relapsed multiple myeloma patients

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.

Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patientswith MM.

Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patientswith MM.

Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patientswith MM.

Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patientswith MM.

Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patientswith MM.

Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patientswith MM.

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways.This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.